1
|
Ekinci M, Çalışkan EE, Çakar B, İlem-Özdemir D, Uyanıkgil Y, Çetin Uyanıkgil EÖ. [ 99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation. ACS OMEGA 2023; 8:6279-6288. [PMID: 36844604 PMCID: PMC9948160 DOI: 10.1021/acsomega.2c06179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Accepted: 01/25/2023] [Indexed: 06/18/2023]
Abstract
The aim of this research was to develop technetium-99m ([99mTc]Tc)-radiolabeled niosomes and evaluate the cancer cell incorporation capacity of radiolabeled niosomes. For this purpose, niosome formulations were developed by film hydration method, and prepared niosomes were characterized to particle size, polydispersity index (PdI), ζ-potential value, and image profile. Then, niosomes were radiolabeled with [99mTc]Tc using stannous salts (chloride) as a reducing agent. The radiochemical purity (RP) and stability in different mediums of the niosomes were assessed by ascending radioactive thin-layer chromatography (RTLC) and radioactive ultrahigh-performance liquid chromatography (R-UPLC) methods. Also, the partition coefficient value of radiolabeled niosomes was determined. The cell incorporation of [99mTc]Tc-labeled niosome formulations, as well as reduced/hydrolyzed (R/H)-[99mTc]NaTcO4 in the HT-29 (human colorectal adenocarcinoma) cells, was then assessed. According to the obtained results, the spherical niosomes had a particle size of 130.5 ± 1.364 nm, a PdI value of 0.250 ± 0.023, and a negative charge of -35.4 ± 1.06 mV. The niosome formulations were effectively radiolabeled with [99mTc]Tc using 500 μg mL-1 stannous chloride for 15 min, and RP was found to be over 95%. [99mTc]Tc-niosomes showed good in vitro stability in every system for up to 6 h. The log P value of radiolabeled niosomes was found as -0.66 ± 0.02. Compared to R/H-[99mTc]NaTcO4 (34.18 ± 1.56%), the incorporation percentages of [99mTc]Tc-niosomes (88.45 ± 2.54%) were shown to be higher in cancer cells. In conclusion, the newly developed [99mTc]Tc-niosomes showed good prototype for potential use in nuclear medicine imaging in the near future. However, further investigations, such as drug encapsulation and biodistribution studies, should be performed, and our studies are continuing.
Collapse
Affiliation(s)
- Meliha Ekinci
- Faculty
of Pharmacy, Department of Radiopharmacy, Ege University, Bornova, 35040 Izmir, Türkiye
| | - Emine Esin Çalışkan
- Faculty
of Pharmacy, Department of Pharmaceutical Technology, Department of
Biopharmaceutics and Pharmacokinetics, Ege
University, 35100 Izmir, Türkiye
| | - Burak Çakar
- Faculty
of Medicine, Department of Histology and Embryology, Ege University, 35040 Izmir, Türkiye
| | - Derya İlem-Özdemir
- Faculty
of Pharmacy, Department of Radiopharmacy, Ege University, Bornova, 35040 Izmir, Türkiye
| | - Yiğit Uyanıkgil
- Faculty
of Medicine, Department of Histology and Embryology, Ege University, 35040 Izmir, Türkiye
- Health
Science Institute, Department of Stem Cell, Ege University, 35040 Izmir, Türkiye
- Cord
Blood, Cell and Tissue Research and Application Centre, Ege University, 35040 Izmir, Türkiye
| | - Emel Öykü Çetin Uyanıkgil
- Faculty
of Pharmacy, Department of Pharmaceutical Technology, Department of
Biopharmaceutics and Pharmacokinetics, Ege
University, 35100 Izmir, Türkiye
| |
Collapse
|
2
|
Erfani M, Shabani Z, Shamsaei M, Shirmardi SP, Shafiei M. 99m Tc-tricarbonyl labeling of paclitaxel as an antimicrotubule agent and its evaluation in B16-F10 melanoma tumor-bearing mice. J Labelled Comp Radiopharm 2016; 59:582-588. [PMID: 27782316 DOI: 10.1002/jlcr.3468] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 09/07/2016] [Accepted: 09/16/2016] [Indexed: 01/04/2023]
Abstract
In the present study paclitaxel (taxol) was labeled with [99m Tc(CO)3 (H2 O)3 ]+ core. Labeling was optimized, and radiochemical analysis was determined by thin layer chromatography and high performance liquid chromatography. Radiocomplex was evaluated and verified further as a tumor characterization agent in B16-F10 melanoma tumor-bearing mice. The [99m Tc(CO)3 (H2 O)3 ]+ -paclitaxel complex with high specific activity (0.77 GBq/μmol) and labeling yield (96.8 ± 1.3) was obtained. No decrease in labeling was observed up to 6 hours, and the stability of the radiocomplex was found adequate. Our main achievement was high accumulation of radiolabeled paclitaxel in tumor (4.51 ± 0.65 percentage injected dose per gram [%ID/g] at 2-h postinjection) followed by significant reduction (1.86 ± 0.27%ID/g) at 4-hour postinjection. Because paclitaxel is a substrate for multidrug resistance, 99m Tc-tricarbonyl-paclitaxel imaging would be useful for tumor characterization rather than tumor detection.
Collapse
Affiliation(s)
- Mostafa Erfani
- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
| | - Zahra Shabani
- Faculty of Nuclear engineering and Physics, Amirkabir University of Technology, Tehran, Iran
| | - Mojtaba Shamsaei
- Faculty of Nuclear engineering and Physics, Amirkabir University of Technology, Tehran, Iran
| | - Seyed Pezhman Shirmardi
- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
| | - Mohammad Shafiei
- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
| |
Collapse
|
3
|
Akbar MU, Ahmad MR, Shaheen A, Mushtaq S. A review on evaluation of technetium-99m labeled radiopharmaceuticals. J Radioanal Nucl Chem 2016. [DOI: 10.1007/s10967-016-5019-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
4
|
Banerjee I, De K, Mukherjee D, Dey G, Chattopadhyay S, Mukherjee M, Mandal M, Bandyopadhyay AK, Gupta A, Ganguly S, Misra M. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomater 2016; 38:69-81. [PMID: 27109765 DOI: 10.1016/j.actbio.2016.04.026] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 03/05/2016] [Accepted: 04/18/2016] [Indexed: 11/19/2022]
Abstract
UNLABELLED Somatostatin receptors (SSTRs) especially subtype 2 (SSTR2) are overexpressed in glioma. By taking advantage of the specific expression of SSTR2 on both glioma neovasculature endothelial cells and glioma cells, we constructed Tyr-3-octreotide (TOC)-modified solid lipid nanoparticles (SLN) loaded with paclitaxel (PTX) to enable tumor neovasculature and tumor cells dual-targeting chemotherapy. In this work, a TOC-polyethylene glycol-lipid (TOC-PEG-lipid) was successfully synthesized and used as a targeting molecule to enhance anticancer efficacy of PTX loaded sterically stabilized lipid nanoparticles. The prepared PTX-loaded SLN modified with TOC (PSM) was characterized by standard methods. In rat C6 glioma cells, PSM improved PTX induced apoptosis. Both tube formation assay and CD31 staining of treated orthotopic glioma tissues confirmed that PSM significantly improved the antiangiogenic ability of PTX in vitro and in vivo, respectively. Radiolabelled PSM achieved a much higher and specific accumulation within the glioma as suggested by the biodistribution and imaging studies. Furthermore, PSM exhibited improved anti-glioma efficacy over unmodified nanoparticles and Taxol in both subcutaneous and orthotopic tumor models. These findings collectively indicate that PSM holds great potential in improving the efficacy of anti-glioma therapy. STATEMENT OF SIGNIFICANCE Somatostatin receptors (SSTRs) especially subtype 2 (SSTR2) are overexpressed in various mammalian cancer cells. Proliferating endothelial cells of neovasculature also express SSTR2. Tyr-3-octreotide (TOC) is a known ligand for SSTR2. We have successfully prepared paclitaxel-loaded solid lipid nanoparticles modified with TOC (PSM) having diameter less than 100nm. We found that PSM improved anti-cancer efficacy of paclitaxel in SSTR2 positive glioma of rats. This improved anti-glioma efficiency of PSM can be attributed to dual-targeting (i.e. tumor cell and neovasculature targeting) efficiency of PSM and promoted anti-cancer drug accumulation at tumor site due to TOC modification of solid lipid nanoparticles. This particular study aims at widening the scope of octreotide-derivative modified nanocarrier by exploring dual-targeting potential of PSM.
Collapse
Affiliation(s)
- Indranil Banerjee
- Department of Infectious Diseases and Immunology (Nuclear Medicine Division), CSIR-IICB, 4 Raja S C Mullick Road, Kolkata 700032, India.
| | - Kakali De
- Department of Infectious Diseases and Immunology (Nuclear Medicine Division), CSIR-IICB, 4 Raja S C Mullick Road, Kolkata 700032, India
| | - Dibyanti Mukherjee
- Department of Infectious Diseases and Immunology (Nuclear Medicine Division), CSIR-IICB, 4 Raja S C Mullick Road, Kolkata 700032, India
| | - Goutam Dey
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India
| | - Sankha Chattopadhyay
- Radiopharmaceuticals Laboratory, Regional Centre, Board of Radiation and Isotope Technology, Variable Energy Cyclotron Centre, 1/AF, Bidhan Nagar, Kolkata 700064, India
| | | | - Mahitosh Mandal
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India
| | - Amal Kumar Bandyopadhyay
- Division of Pharmaceutics, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
| | - Amit Gupta
- Regional Radiation Medicine Centre, Thakurpukur Cancer Research Centre, Kolkata 700063, India
| | - Santanu Ganguly
- Regional Radiation Medicine Centre, Thakurpukur Cancer Research Centre, Kolkata 700063, India
| | - Mridula Misra
- Department of Infectious Diseases and Immunology (Nuclear Medicine Division), CSIR-IICB, 4 Raja S C Mullick Road, Kolkata 700032, India.
| |
Collapse
|
5
|
Dey G, Bharti R, Banerjee I, Das AK, Das CK, Das S, Jena BC, Misra M, Sen R, Mandal M. Pre-clinical risk assessment and therapeutic potential of antitumor lipopeptide ‘Iturin A’ in an in vivo and in vitro model. RSC Adv 2016. [DOI: 10.1039/c6ra13476a] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Microbial lipopeptide “Iturin A” is a versatile bio-active molecule with potent antitumor action. Pre-clinical study of this lipopeptide showed very minimum toxicity in rodent model.
Collapse
Affiliation(s)
- Goutam Dey
- School of Medical Science & Technology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| | - Rashmi Bharti
- School of Medical Science & Technology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| | - Indranil Banerjee
- Division of Nuclear Medicine
- Indian Institute of Chemical Biology
- Kolkata-700032
- India
| | - Anjan Kumar Das
- Department of Pathology
- Calcutta National Medical Collage
- Kolkata-70014
- India
| | - Chandan Kanta Das
- School of Medical Science & Technology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| | - Subhayan Das
- School of Medical Science & Technology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| | - Bikash Chandra Jena
- School of Medical Science & Technology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| | - Mridula Misra
- Division of Nuclear Medicine
- Indian Institute of Chemical Biology
- Kolkata-700032
- India
| | - Ramkrishna Sen
- Department of Biotechnology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| | - Mahitosh Mandal
- School of Medical Science & Technology
- Indian Institute of Technology Kharagpur
- Kharagpur-721302
- India
| |
Collapse
|